top of page
Researcher

COHERENCE

Start Date:

July 2018

End Date:

February 2020

Duration:

18 months

ID-CARE Role:
Website:

Leader

Description

Title: Combination therapy to treat sepsis due to carbapenem-resistant bacteria in adult and paediatric population: evidence and common practice


Design: Cross sectional survey, systematic reviews and network meta-analyses


Primary objective: Specific objectives are:

  • to investigate the prescription habits and attitudes among clinicians usually dealing with CR-GNB

  • to comprehensively summarize the evidence on the available antibiotic options for the treatment of sepsis due to CR-GNB, including in vitro and in vivo data, and clinical studies

Bringing together clinical practice and data from literature, the final aim is to point out the major gaps in knowledge in order to drive the development of future studies on the most promising treatment schemes within the GARDP projects.

Partners

University of Verona - ITALY (Coordinator)

GARDP Global Antibiotic Research & Development Partnership - SWITZERLAND

Sponsor
Horizon2020.jpg
Horizon2020.jpg
Horizon2020.jpg
Horizon2020.jpg
Publications

Clinical Microbiology and Infection

30/1/22

Clinical management of severe infections caused by carbapenem-resistant gram-negative bacteria: a worldwide cross-sectional survey addressing the use of antibiotic combinations

BMC Infectious Diseases

8/6/21

The role of combination therapy in the treatment of severe infections caused by carbapenem resistant gram-negatives: a systematic review of clinical studies

International Journal of Antimicrobial Agents

6/6/21

Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli

ID-CARE Participants

Evelina Tacconelli

Director

Elena Carrara

Clinical Researcher, MD

Alessia Savoldi

Medical Doctor

From our Blog
In the News
bottom of page